$AMGN, $PHI, $VCEL, $QNRX Fuel a +3.33% Surge in the Cellular Sector Performance Over the Past Week
Robots for this industry :
Trend Trader, Popular Stocks: Price Action Trading Strategy (TA&FA) - 30-day Annualized Return +43%
Swing trader: Downtrend Protection v.2 (TA) - 30-day Annualized Return +36%
The cellular sector, encompassing a group of companies including AMGN, PHI, VCEL, and QNRX, has recently experienced a significant increase in performance, with a notable 3.33% gain over the past week. However, a closer look reveals a negative outlook on this group, as supported by the Aroon Indicator and other technical analysis tools.
Performance and Outlook
Despite the recent performance uptick, Tickeron predicts a further decline of over 4.00% within the next month with a likelihood of 78%. This pessimistic outlook is reinforced by technical indicators such as the Aroon Indicator and the RSI Indicator.
Group of Tickers in Focus
The following tickers make up this thematic group:
AMGN - A Shifting Trend
Amgen Inc. (AMGN) has recently left the overbought zone, according to the 10-day RSI Indicator. This change suggests a potential shift from an upward trend to a downward one. In similar instances, there was a 67% likelihood of the stock moving lower in the days that followed. AMGN's price is currently trading between $306.80 resistance and $232.58 support lines, with a recent uptrend followed by a downtrend in the past month.
PHI - On an Upward Trajectory
PLDT Inc. (PHI) exhibits a more positive trend. On September 15, 2023, the stock's price broke its lower Bollinger Band, indicating a potential upward movement. In 76% of similar cases, the price continued to rise in the following month. PHI's price is trading between $23.15 resistance and $20.87 support lines, with an uptrend in the past month followed by a minor downtrend during the week of October 12-19, 2023.
VCEL - A Promising Uptrend
Vericel Corporation (VCEL) stands out with a 13.02% uptrend, advancing for three consecutive days on October 17, 2023. Historically, when VCEL advanced for three days, the price continued to rise in 79% of cases within the following month. VCEL's current price is trading between $33.38 resistance and $33.14 support lines, with consistent upward movement over the past month.
QNRX - Penny Stock Volatility
Quoin Pharmaceuticals (QNRX) has exhibited extreme volatility in recent weeks. It experienced a significant weekly gain of 24.14% on July 25, 2023, followed by a substantial loss of 17.27% on July 29, 2023. Such fluctuations are common among penny stocks, where rapid gains and losses are frequent.
Market Capitalization Overview
The average market capitalization across this group is approximately $39.6 billion, with AMGN as the highest-valued company at $152.1 billion and QNRX as the lowest valued at $3.8 million.
Price Movements
- The average weekly price growth across all stocks in the group was 3.4%.
- The average monthly price growth was -0.61%.
- The average quarterly price growth was 1.2%.
Notably, QNRX experienced the highest weekly price growth at 10.63%, while AMGN suffered the most significant loss at -1.86%.
Volume Trends
- The average weekly volume growth across all stocks in the group was -0.23%.
- The average monthly volume growth was 23.2%.
- The average quarterly volume growth was 19.33%.
On specific dates, QNRX saw exceptional daily volume spikes, resulting in remarkable increases in trading activity. Such fluctuations may be indicative of increased investor interest and potential price movements.
In summary, the cellular sector, represented by these tickers, shows mixed performance and outlook. While AMGN hints at a potential downturn, PHI and VCEL suggest favorable trends, and QNRX exhibits penny stock volatility. Investors should consider these factors and perform additional research before making investment decisions in this sector.
AMGN in upward trend: price may ascend as a result of having broken its lower Bollinger Band on June 23, 2025
AMGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 37 cases where AMGN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AMGN's RSI Oscillator exited the oversold zone, of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on July 02, 2025. You may want to consider a long position or call options on AMGN as a result. In of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for AMGN just turned positive on July 02, 2025. Looking at past instances where AMGN's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .
AMGN moved above its 50-day moving average on July 01, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for AMGN crossed bullishly above the 50-day moving average on June 05, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in of 304 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 222 cases where AMGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: AMGN's P/B Ratio (24.331) is slightly higher than the industry average of (5.632). P/E Ratio (22.661) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (2.526) is also within normal values, averaging (3.004). Dividend Yield (0.031) settles around the average of (0.161) among similar stocks. P/S Ratio (5.402) is also within normal values, averaging (3.643).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. AMGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of human therapeutic products based on cellular biology
Industry PharmaceuticalsMajor
Advertisement